Financials data is unavailable for this security.
View more
Year on year Lushang Freda Pharmaceutical Co Ltd had revenues fall -64.65% from 12.95bn to 4.58bn, though the company grew net income 567.44% from 45.46m to 303.39m.
| Gross margin | 48.73% |
|---|---|
| Net profit margin | 6.87% |
| Operating margin | 7.81% |
| Return on assets | 3.23% |
|---|---|
| Return on equity | 5.88% |
| Return on investment | 5.93% |
More ▼
Cash flow in CNYView more
In 2023, Lushang Freda Pharmaceutical Co Ltd did not generate a significant amount of cash. However, Cash Flow from Investing totalled 2.67bn, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 474.15m in cash from operations while cash used for financing totalled 3.10bn.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 4.02 |
|---|---|
| Tangible book value per share | 3.68 |
More ▼
Balance sheet in CNYView more
| Current ratio | 3.45 |
|---|---|
| Quick ratio | 2.96 |
| Total debt/total equity | 0.1147 |
|---|---|
| Total debt/total capital | 0.0896 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items increased 646.10%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 1.03% |
|---|---|
| Div growth rate (5 year) | 14.87% |
| Payout ratio (TTM) | 42.98% |
| EPS growth(5 years) | 13.01 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 80.55 |
More ▼
